← Leaderboards
Ru L Bryan
Veterans Medical Research Fdn/San Diego
$2,426,273
Attributed
$2,567,808
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $351K · FY2005–23$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,567,808 · 4
VA$0 · 1
By mechanism
R01$1,709,895 · 1
R21$376,542 · 1
R41$283,071 · 1
R03$198,300 · 1
I01$0 · 1
Top collaborators
- Ryan William Dellinger1 shared
Others in their field
Top investigators on “Chondrocytes”
- Martin K. Lotz · Scripps Research Institute$20,021,168
- Farshid Guilak · Duke University$19,379,279
- Veronique M Lefebvre · University Of Texas Md Anderson Can Ctr$17,871,341
- Qian Chen · Rhode Island Hospital$17,579,507
- Richard F Loeser · Rush University Medical Center$16,293,126
- Maurizio Pacifici · University Of Pennsylvania$13,073,083
Research focus
ChondrocytesInflammationMediatingIn VivoInflammatoryDegenerative PolyarthritisCartilagePharmaceutical PreparationsCatabolismInsightKnee OsteoarthritisAgingSignal TransductionJointsIn VitroResponseKnockout MiceCellsCytokineArticular CartilageAggrecanaseModificationMitochondriaNitric Oxide
Grant awards (19)
Development of Nicotinamide-Riboside plus Pterostilbene as a Disease Modifying Osteoarthritis Therapeutic$283,071
R41 · FY2023 · AR
ATP-Citrate Lyase As A Novel Metabolic Target for Osteoarthritis$0
I01 · FY2022 · VA · contact PI
ATP-Citrate Lyase As A Novel Metabolic Target for Osteoarthritis$0
I01 · FY2021 · VA · contact PI
ATP-Citrate Lyase As A Novel Metabolic Target for Osteoarthritis$0
I01 · FY2020 · VA · contact PI
ATP-Citrate Lyase As A Novel Metabolic Target for Osteoarthritis$0
I01 · FY2019 · VA · contact PI
AMPK as an Interventional Target to Suppress the Development of Osteoarthritis$0
I01 · FY2018 · VA · contact PI
AMPK as an Interventional Target to Suppress the Development of Osteoarthritis$0
I01 · FY2017 · VA · contact PI
AMPK as an Interventional Target to Suppress the Development of Osteoarthritis$0
I01 · FY2016 · VA · contact PI
AMPK as an Interventional Target to Suppress the Development of Osteoarthritis$0
I01 · FY2015 · VA · contact PI
Cartilage Innate Immunity in Osteoarthritis$323,375
R01 · FY2013 · AI · contact PI
Cartilage Innate Immunity in Osteoarthritis$344,015
R01 · FY2012 · AI · contact PI
Cartilage Innate Immunity in Osteoarthritis$344,015
R01 · FY2011 · AI · contact PI
Cartilage Innate Immunity in Osteoarthritis$347,490
R01 · FY2010 · AI · contact PI
Cartilage Innate Immunity in Osteoarthritis$351,000
R01 · FY2009 · AI · contact PI
Innate Immunity in gouty Inflammation$237,942
R21 · FY2008 · AI · contact PI
Innate Immunity in gouty Inflammation$138,600
R21 · FY2007 · AI · contact PI
IL-8 in chondrocalcinosis$66,100
R03 · FY2005 · AR
IL-8 in chondrocalcinosis$66,100
R03 · FY2004 · AR
IL-8 in chondrocalcinosis$66,100
R03 · FY2003 · AR